Alps Group Inc

Alps Group Inc. (the "Company" or "Alps Group") operates in the life sciences sector, with a particular focus on cellular therapy and vaccine development, as evidenced by the expertise of its Chief Executive Officer and Chief Vaccine Development Officer. The Company's business activities are conducted through its subsidiaries, following a business combination that resulted in Alps Group Inc. becoming the publicly traded entity. The Company's principal executive office is located in Kuala Lumpur, Wilayah Persekutuan, Malaysia, indicating a primary operational base in Southeast Asia.

The core business model of Alps Group Inc. is centered around life sciences, specifically cellular therapy and vaccine development. The Company generates revenue through its subsidiaries, which conduct the entirety of its business operations. Key customer segments are implied to be within the healthcare and wellness sectors, including medical tourism, as its Director, Chew Yoke Ling, oversees sales and marketing activities for Alps' products and services, and coordinates medical tourism efforts for both local and international clients. The Company also engages in information system development and supporting services ancillary to the Internet of Things (IoT) through Aiiot Technologies Sdn. Bhd., and healthcare business developments through Alps Globemedic Sdn. Bhd.

The Company's product and service lines include ongoing extensive research on anti-aging cellular therapy since 2006, and active participation in cancer research, led by Dr. Tham Seng Kong, the CEO and Interim CFO. Additionally, Professor Poh Chit Laa serves as the Chief Vaccine Development Officer, indicating a strategic focus on vaccine development. The Company also has a presence in information system development and IoT supporting services through Aiiot Technologies Sdn. Bhd., and healthcare business developments via Alps Globemedic Sdn. Bhd. While specific revenue or margin contributions for each product or service line are not disclosed in this filing, the emphasis on cellular therapy and vaccine development, alongside medical tourism and IoT-related healthcare services, suggests a diversified approach within the broader life sciences and healthcare industries.

For the reported fiscal period, as of March 31, 2025, on an unaudited pro forma combined basis after giving effect to the Business Combination, Alps Group Inc. reported cash and cash equivalents of $3,034,585 ¹. The Company had total equity of $(265,676) ². Total indebtedness amounted to $10,165,195 ³, comprising non-current debt of $850,331 ⁴ and current debt of $9,314,864 ⁵. Total capitalization was $9,899,519 ⁶. Specific figures for total revenue, gross profit, gross margin percentage, operating income, operating margin, net income, basic and diluted EPS, and free cash flow are not provided in this filing.

The filing does not provide year-over-year comparisons for revenue growth by segment, margin expansion or contraction, or notable shifts in business mix.

Significant operational developments during the period include the consummation of a Business Combination on October 28, 2025, where Globalink Investment Inc. merged with PubCo, and Merger Sub merged with Alps Holdco, resulting in Alps Group Inc. as the surviving publicly traded entity. The aggregate consideration for the Business Combination was US$1.6 billion ⁷, payable in newly issued PubCo ordinary shares at $10.00 per share ⁸. As part of this, 8,000,000 ⁹ ordinary shares, representing five percent (5%) ¹⁰ of the Merger Consideration Shares, were issued and held in escrow to satisfy indemnification obligations. Additionally, PubCo, Globalink, and Alps Holdco entered into Subscription Agreements with PIPE Investors for an aggregate subscription amount of US$3,107,875 ¹¹ in PubCo ordinary shares in a private placement, which closed immediately prior to the Business Combination. The Company also changed its name to "Alps Group Inc."

The filing does not provide specific revenue, margin, or EPS guidance for the upcoming period.

The Company's growth areas are implicitly tied to its focus on cellular therapy and vaccine development, as highlighted by the roles of Dr. Tham Seng Kong as Chief Executive Officer and Group Chief Research Scientist, and Professor Poh Chit Laa as Chief Vaccine Development Officer. Dr. Tham has been involved in extensive research on anti-aging cellular therapy since 2006 and actively participates in cancer research, suggesting continued investment and development in these areas. Professor Poh's expertise in medical microbiology, bacteriology, and biotechnology, coupled with her role, indicates a strategic emphasis on advancing the Company's vaccine pipeline.

Another growth vector is the Company's engagement in medical tourism, overseen by Director Chew Yoke Ling, who manages sales and marketing for Alps' products and services and coordinates medical tourism efforts for both local and international clients. This suggests an ongoing strategy to attract a global clientele for its healthcare offerings. Furthermore, the Company's involvement in information system development and supporting services ancillary to the Internet of Things (IoT) through Aiiot Technologies Sdn. Bhd., and healthcare business developments through Alps Globemedic Sdn. Bhd., points to a strategy of leveraging technology and expanding its footprint in broader healthcare services.

The filing does not explicitly address margin trajectory, cost structure evolution, efficiency or restructuring targets, supply chain posture, manufacturing capacity, technology infrastructure investments, or headcount or workforce strategy in a forward-looking manner.

Regarding planned capital allocation, the filing indicates that the aggregate consideration for the Business Combination was US$1.6 billion ¹², with 8,000,000 ¹³ ordinary shares (five percent (5%) ¹⁴ of Merger Consideration Shares) held in escrow for indemnification obligations. The PIPE Investment brought in an aggregate subscription amount of US$3,107,875 ¹⁵. The Company's authorized share capital is US$50,000 ¹⁶, divided into 500,000,000 ¹⁷ shares, comprising 495,000,000 ¹⁸ PubCo ordinary shares of US$0.0001 ¹⁹ par value each, and 5,000,000 ²⁰ PubCo preferred shares of US$0.0001 ²¹ par value each. As of October 28, 2025, 166,400,326 ²² Ordinary Shares were issued and outstanding. The Company has no current plans to pay cash dividends on its ordinary shares for the foreseeable future.

The filing explicitly flags several structural headwinds and execution risks. These include changes in domestic and foreign business, market, financial, political, and legal conditions; inability to obtain financing, equity, debt, or convertible debt financings on favorable terms or at all, which could lead to additional costs or unavailability of funding under existing arrangements; growth in demand for products and services being lower or later than expected, including delays in development, clinical trials, or commercialization of product candidates; increases in prices of labor or materials, or adverse movements in foreign exchange; disruption to global supply chains; downward pricing pressure from customers; inability to maintain the listing of the Company’s securities on a U.S. securities exchange; failure to realize the anticipated benefits of the Business Combination and related transactions; risks related to the rollout of the business strategy and timing of expected business milestones; effects of competition on future business and the ability to grow and manage growth, establish and maintain customer relationships, and retain management and key employees; the outcome of any legal proceedings; the impact of any pandemic or other public health crisis and governmental responses; risks related to the Combined Company’s industry; changes in laws and regulations; and risks and uncertainties related to being based in and having substantially all operations in Malaysia.

The Company faces several material risks, including changes in domestic and foreign business, market, financial, political, and legal conditions, and the inability to secure financing on favorable terms, which could result in additional costs or a lack of funding under existing arrangements. There is a risk that demand for products and services may grow slower or later than anticipated, including delays in development, clinical trials, or commercialization of product candidates. Operational risks include increases in labor or material prices, adverse foreign exchange movements, disruptions to global supply chains, and downward pricing pressure from customers. Furthermore, the Company faces risks related to maintaining its listing on a U.S. securities exchange, failing to realize the anticipated benefits of the Business Combination, and challenges in executing its business strategy and meeting milestones. Competitive pressures, the ability to retain key employees, the outcome of legal proceedings, and the impact of public health crises are also significant. Regulatory changes and specific risks associated with having substantially all operations based in Malaysia are also material concerns.

Management's overall tone, as conveyed through the filing, emphasizes the strategic importance of the recently completed Business Combination and the Company's focus on life sciences, particularly cellular therapy and vaccine development. Dr. Tham Seng Kong, as Chief Executive Officer and Interim Chief Financial Officer, highlights his deep expertise in life sciences and cellular therapy, including ongoing research in anti-aging cellular therapy since 2006 and active participation in cancer research. The appointment of Professor Poh Chit Laa as Chief Vaccine Development Officer underscores a strategic priority in advancing vaccine-related initiatives. While no specific forward-looking revenue, margin, or EPS guidance ranges are provided, the Company explicitly states that there are no current plans to pay cash dividends on the PubCo ordinary shares for the foreseeable future. The strategic priorities appear to be centered on leveraging the expertise in cellular therapy and vaccine development, expanding medical tourism efforts, and integrating technology through IoT-related healthcare business developments.